Thursday, 28 March 2024
Aimmune Therapeutics Inc.
NASDAQ : AIMT
34.18 09 Sep 20 00:00 | Change: 0.01 | Open: 34.19 | High: 34.21 | Ask: 0.00 | Volume: 1,130,200 |
Change(%): 0.03 | Prev: 34.17 | Low: 34.17 | Bid: 0.00 | Avg vol: 0 |
No Risk Alert Here: Before we dive into any analysis we simply note that Aimmune Therapeutics Inc (NASDAQ:AIMT) risk is neither elevated nor depressed.
more»
The results here are provided for general informational purposes, as a convenience to the readers. The materials are not a substitute for obtaining professional advice from a qualified person, firm or corporation.
more»
01:56 | 13/3/18
Market Exclusive
On March 12, 2018, Aimmune Therapeutics, Inc. (“Aimmune” or the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2017, and its financial position as of December 31, 2017.
more»
01:11 | 13/3/18
Albany Times Union
BRISBANE, Calif. (AP) _ Aimmune Therapeutics Inc. (AIMT) on Monday reported a loss of $41.2 million in its fourth quarter. On a per-share basis, the Brisbane, California-based company said it had a loss of 81 cents.
more»
01:00 | 13/3/18
Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the fourth quarter and full year 2017.
more»
There are currently no comments on this topic.
Be the first person to Add a Comment...
You must be a registered user to post a comment: REGISTER NOW
If you are already registered, please LOGIN NOW
|
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |